Levi & Korsinsky Investigates Possible Securities Fraud Violations by Amphastar Pharmaceuticals, Inc. (AMPH)
Portfolio Pulse from
Levi & Korsinsky is investigating Amphastar Pharmaceuticals for potential securities fraud related to FDA delays on its generic teriparatide ANDA, AMP-015.
February 14, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation for potential securities fraud due to FDA delays on its generic teriparatide ANDA, AMP-015.
The investigation by Levi & Korsinsky into Amphastar Pharmaceuticals for potential securities fraud is likely to negatively impact the stock price in the short term. The investigation is related to FDA delays on a key product, which could affect investor confidence and lead to a sell-off.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100